Ticker LaunchUplisting · ACOG
Alpha Cognition Inc.
Formerly Neurodyn Cognition Inc.
Alpha Cognition Inc. (ACOG), already reporting to the SEC, moved up to Nasdaq Capital Market on Nov 13, 2024 with an offering at $5.75 per share. American Capital Partners was lead-left underwriter. Morton Law and Dorsey & Whitney advised the company and Loeb & Loeb advised the underwriters.
Alpha Cognition Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases such as Alzheimer's disease. It is focused on commercial manufacturing and sales of ZUNVEYL oral tablets, building a long-term care commercial team.
- Status
- Uplisting
- Ticker
- ACOG
- Exchange
- Nasdaq Capital Market
- Listed
- Nov 13, 2024
- Price
- $5.75
- Market cap at IPO price
- $89.3M
- First filed
- Apr 30, 2024
- Underwriters
- American Capital Partners
- Company counsel
- Morton Law and Dorsey & Whitney
- Underwriters' counsel
- Loeb & Loeb
- Sector
- Biotech & pharma
- Country / state
- TX
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Apr 30, 2024
- Latest amendment Nov 6, 2024
- Final prospectus (424B4) Nov 13, 2024
- All filings on EDGAR CIK 1655923
Other Biotech & pharma uplistings in 2024
- Synergy CHC Corp.SNYR · Oct 23, 2024 · $10.3M
- Impact Biomedical Inc.IBO · Sep 17, 2024 · $4.5M
- OS Therapies IncOSTX · Aug 1, 2024 · $6.4M